Hebei Changshan Biochem Pharma (SHE:300255) — Market Cap & Net Worth
Market Cap & Net Worth: Hebei Changshan Biochem Pharma (300255)
Hebei Changshan Biochem Pharma (SHE:300255) has a market capitalization of $3.48 Billion (CN¥23.76 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #4592 globally and #796 in its home market, demonstrating a -31.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hebei Changshan Biochem Pharma's stock price CN¥25.85 by its total outstanding shares 919060878 (919.06 Million). Review Hebei Changshan Biochem Pharma debt and liabilities to assess the company's total debt and financial obligations.
Hebei Changshan Biochem Pharma Market Cap History: 2015 to 2026
Hebei Changshan Biochem Pharma's market capitalization history from 2015 to 2026. Data shows growth from $1.28 Billion to $3.48 Billion (9.78% CAGR).
Hebei Changshan Biochem Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hebei Changshan Biochem Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.61x
Hebei Changshan Biochem Pharma's market cap is 2.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.28 Billion | $915.99 Million | $156.30 Million | 1.40x | 8.20x |
| 2016 | $1.04 Billion | $1.12 Billion | $175.49 Million | 0.93x | 5.95x |
| 2017 | $838.35 Million | $1.42 Billion | $196.92 Million | 0.59x | 4.26x |
| 2018 | $543.84 Million | $1.65 Billion | $139.99 Million | 0.33x | 3.88x |
| 2019 | $726.27 Million | $2.07 Billion | $225.29 Million | 0.35x | 3.22x |
| 2020 | $826.79 Million | $2.36 Billion | $252.84 Million | 0.35x | 3.27x |
| 2021 | $1.09 Billion | $2.97 Billion | $233.57 Million | 0.37x | 4.66x |
| 2022 | $736.24 Million | $2.34 Billion | $17.51 Million | 0.32x | 42.04x |
| 2023 | $1.75 Billion | $1.41 Billion | -$1.24 Billion | 1.24x | N/A |
| 2024 | $2.69 Billion | $1.03 Billion | -$249.48 Million | 2.61x | N/A |
Competitor Companies of 300255 by Market Capitalization
Companies near Hebei Changshan Biochem Pharma in the global market cap rankings as of June 19, 2026.
Key companies related to Hebei Changshan Biochem Pharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Hebei Changshan Biochem Pharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Hebei Changshan Biochem Pharma's market cap moved from $1.28 Billion to $ 3.48 Billion, with a yearly change of 9.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.48 Billion | -58.37% |
| 2025 | CN¥8.35 Billion | +210.66% |
| 2024 | CN¥2.69 Billion | +53.65% |
| 2023 | CN¥1.75 Billion | +137.65% |
| 2022 | CN¥736.24 Million | -32.31% |
| 2021 | CN¥1.09 Billion | +31.55% |
| 2020 | CN¥826.79 Million | +13.84% |
| 2019 | CN¥726.27 Million | +33.55% |
| 2018 | CN¥543.84 Million | -35.13% |
| 2017 | CN¥838.35 Million | -19.74% |
| 2016 | CN¥1.04 Billion | -18.52% |
| 2015 | CN¥1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Hebei Changshan Biochem Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.48 Billion USD |
| MoneyControl | $3.48 Billion USD |
| MarketWatch | $3.48 Billion USD |
| marketcap.company | $3.48 Billion USD |
| Reuters | $3.48 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more